Aspira Women’s Health (NASDAQ:AWH) Downgraded by StockNews.com to Sell

StockNews.com cut shares of Aspira Women’s Health (NASDAQ:AWH) from a hold rating to a sell rating in a research note released on Thursday morning.

Aspira Women’s Health Stock Down 9.6 %

Shares of AWH opened at $3.10 on Thursday. The firm’s fifty day simple moving average is $4.26 and its two-hundred day simple moving average is $4.30. Aspira Women’s Health has a 12 month low of $2.31 and a 12 month high of $6.75.

Institutional Trading of Aspira Women’s Health

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Aspira Women’s Health by 5.7% during the 1st quarter. Vanguard Group Inc. now owns 3,067,896 shares of the company’s stock worth $3,191,000 after purchasing an additional 164,635 shares in the last quarter. State Street Corp raised its holdings in shares of Aspira Women’s Health by 13.2% in the 1st quarter. State Street Corp now owns 1,786,782 shares of the company’s stock worth $1,858,000 after acquiring an additional 208,231 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Aspira Women’s Health by 18.5% in the 1st quarter. Renaissance Technologies LLC now owns 1,132,801 shares of the company’s stock worth $1,178,000 after acquiring an additional 177,075 shares during the last quarter. B. Riley Wealth Advisors Inc. raised its holdings in shares of Aspira Women’s Health by 19.6% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 792,728 shares of the company’s stock worth $290,000 after acquiring an additional 129,662 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in shares of Aspira Women’s Health by 1,074.4% in the 2nd quarter. Millennium Management LLC now owns 760,611 shares of the company’s stock worth $447,000 after acquiring an additional 695,844 shares during the last quarter. Institutional investors own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering.